Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 101 to 150 of 1904

TitleReference numberPublishedLast updated
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Suspected sepsis: recognition, diagnosis and early managementNG51
Neonatal infection: antibiotics for prevention and treatmentNG195
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and managementNG240
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTE5
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTE14
Digital technologies for managing non-specific low back pain: early value assessmentHTE16
Endoscopic sleeve gastroplasty for obesityIPG783
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Digitally enabled therapies for adults with depression: early value assessmentHTE8
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Caesarean birthNG192
Devices for remote monitoring of Parkinson's diseaseDG51
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Pharyngeal electrical stimulation for neurogenic dysphagiaIPG781
Temperature control to improve neurological outcomes after cardiac arrestIPG782
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Sebelipase alfa for treating Wolman diseaseHST30
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseIPG780
Bipolar disorder: assessment and managementCG185
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTE9
Middle meningeal artery embolisation for chronic subdural haematomasIPG779
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Velmanase alfa for treating alpha-mannosidosisHST29
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Acne vulgaris: managementNG198
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936

Results per page

  1. 10
  2. 25
  3. 50
  4. All